Introduction: Dose escalation with tumor
was estimated using five methods: (1) average weekly dose C110% of recommended label dose; (2) average subsequent dose C130% of starting dose; (3) last dose C110% of starting dose; (4) C2 consecutive instances of dose C130% of starting dose; and (5) [1] [2] [3] . This aggressive approach includes initiation of standard diseasemodifying antirheumatic drugs (DMARDs) and biologic agents. Biologic agents target specific mediators of RA, including the inflammatory cytokine tumor necrosis factor (TNF) [4] .
Etanercept is a TNF receptor:Fc fusion protein and adalimumab is a recombinant human monoclonal antibody against TNF.
The most commonly prescribed self-injected TNF-blockers currently used in the treatment of moderate to severe RA are etanercept and adalimumab [5] . were considered to have a length of persistence equal to that of their follow-up period.
MATERIALS AND METHODS

Study Design and Setting
Dose escalation was evaluated in patients
who were persistent on their index TNFblocker for at least 12 months and who started at or above the labeled dose. Dose escalation was defined using five previously published methods: (1) average weekly dose C110% of the minimum FDA-recommended label dose [11, 17] ; (2) average subsequent dose C130% of the starting dose [11] ; (3) last dose C110% of the starting dose [20] ; (4) Consistent with the dose escalation results, the average weekly dose over the study period and the total dispensed quantities within 12 months for the patients who were persistent on etanercept were close to the label dose of 50 mg weekly. Higher rates of dose escalation compared with etanercept were observed, and average weekly doses and total dispensed quantities of adalimumab were slightly higher than the label dose. For new patients on adalimumab, both measures were approximately 7% higher than would be expected from the label dose and for continuing patients, the average weekly dose was approximately 20% higher and total dispensed quantity within the first year was about 13% higher than the label dose.
In this study, five different methods of calculating dose escalation were used; most of these methods have been used in previously published studies [11-13, 17, 20, 21] . We used a real-world definition of dose escalation (syringe/vial increase or shortened frequency of dosing) and a method used in other studies [13, 22] 
